Targeting
inflammation

 

about us

who

Commercializing a breakthrough advance in inflammation science. MORE

Antibe Therapeutics is a publicly traded biotechnology company exploiting a groundbreaking advance in inflammation science.

LEARN MORE

Pipeline

WHAT

Targeting inflammation arising from a wide range of medical conditions MORE

Leveraging our proprietary hydrogen sulfide platform to develop next-generation therapies to target inflammation arising from a wide range of medical conditions.

LEARN MORE

Science

HOW

Tapping the therapeutic potential of hydrogen sulfide. MORE

Our drug platform draws on 20 years of research into the substantial beneficial effects of hydrogen sulfide across a range of clinical disorders.

LEARN MORE

Investor

why

Providing comprehensive information for our investors. MORE

See the Investor Dashboard for our share price, investor presentation, financial statements and regulatory filings.

LEARN MORE

“As research delivers new insights into the deep biology of hydrogen sulfide, we are widening our exploration of its therapeutic potential.”



John L. Wallace, PhD, MBA, FRCS - Founder and Vice Chair, Antibe Therapeutics

Latest News
See all news

Attention

This is an external link. Click “OK” to continue.

CANCEL OK